Amerikanische Gesellschaft für Hirudotherapie

Cardiopulmonary Bypass Without Heparin.

Review published in Seminars in cardiothoracic and vascular anesthesia (2016)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewKlinische StudienArzneimittelentwicklungRehfeldt et al. · Seminars in cardiothoracic and vascular anesthesia, 2016

Abstract

Due to familiarity, short half-life, ease of monitoring, and the availability of a reversal agent, heparin remains the anticoagulant of choice for cardiac operations requiring cardiopulmonary bypass (CPB). However, occasionally patients require CPB but should not receive heparin, most often because of acute or subacute heparin-induced thrombocytopenia (HIT). In these cases, if it is not feasible to wait for the disappearance of HIT antibodies, an alternative anticoagulant must be selected. A number of non-heparin anticoagulant options have been explored. However, current recommendations suggest the use of a direct thrombin inhibitor such as bivalirudin. This review describes the use of heparin alternatives for the conduct of CPB with a focus on the direct thrombin inhibitors.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsCardiopulmonary BypassHeparinHumansPerioperative CareThrombinThrombocytopenia

Zusammenfassung

Due to familiarity, short half-life, ease of monitoring, and the availability of a reversal agent, heparin remains the anticoagulant of choice for cardiac operations requiring cardiopulmonary bypass (CPB). However, occasionally patients require CPB but should not receive heparin, most often because...

Warum dies für die Hirudotherapie relevant ist

This review examines alternative anticoagulants to heparin for cardiopulmonary bypass, focusing on direct thrombin inhibitors such as bivalirudin for patients who cannot receive heparin (e.g., due to heparin-induced thrombocytopenia). The discussion of direct thrombin inhibitors is tangentially relevant to ASH's domain because hirudin, the archetypal leech-derived anticoagulant, shares the same drug class and mechanistic lineage. However, the article does not mention leeches, hirudin, or hirudotherapy at all, and its clinical scope (cardiac surgery anticoagulation) is far removed from leech therapy applications. Relevance is therefore purely conceptual and indirect — it provides background on the pharmacological family to which a leech-derived compound belongs.

Zitation

Cardiopulmonary Bypass Without Heparin.

Rehfeldt et al. · Seminars in cardiothoracic and vascular anesthesia, 2016

DOI

Verwandter klinischer Kontext

Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist

Clinical EvidenceClinical ApplicationsDrug PipelineDrug DevelopmentDirect Thrombin InhibitorsMicrosurgery OutcomesSurgeryAnticoagulation CompoundsHemostasisCardiovascularCardiologyOtolaryngologyPulmonology

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.